Alzheimer ‘s disease
Eisai to Seek Reconsideration of TGA’s Initial Decision on Lecanemab for Alzheimer’s Disease in Australia
Lecanemab, Alzheimer’s disease, Therapeutic Goods Administration (TGA), Eisai, Biogen, reconsideration, Australia
Johnson & Johnson Discontinues Seltorexant Alzheimer’s Program and Trims Neuroscience Pipeline
Johnson & Johnson, seltorexant, Alzheimer’s disease, neuroscience pipeline, clinical trials, pharmaceutical industry
Sage Therapeutics’ Dalzanemdor Fails in Alzheimer’s, Hopes Now Rest on Huntington’s Disease Trial
Sage Therapeutics, Dalzanemdor, Alzheimer’s Disease, Huntington’s Disease, Clinical Trials, Neurodegenerative Disorders
Athira Pharma Shifts Focus to ALS After Alzheimer’s Setback, Cuts 70% of Workforce
Athira Pharma, Alzheimer’s disease, ALS, layoffs, biotech, neurodegenerative diseases, small molecule therapy
Athira Pharma’s Stock Plummets Following Disappointing Alzheimer’s Drug Trial Results
Athira Pharma, Alzheimer’s disease, fosgonimeton, LIFT-AD study, stock crash
UK Approves Leqembi for Alzheimer’s, but NICE Deems It Too Costly for NHS Use
Leqembi, Alzheimer’s disease, NICE, NHS, cost-effectiveness, UK approval
Leqembi, Biogen and Eisai’s Alzheimer’s Drug, Gains UK Approval but Faces Cost-Effectiveness Hurdle
Leqembi, Alzheimer’s disease, UK approval, NICE, cost-effectiveness, Biogen, Eisai
Sangamo Partners with Genentech for $1.9 Billion Neurology-Focused Deal Using Zinc Finger Technology
Sangamo, Genentech, zinc finger technology, neurology, Alzheimer’s disease, tau gene, biobucks, biopharma, gene therapy, Fabry disease
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
Novo’s GLP-1 Liraglutide May Protect Brain from Alzheimer’s, New Study Finds
GLP-1, Liraglutide, Alzheimer’s Disease, Brain Protection, Cognitive Decline, Novo Nordisk